Atom Investors’s Pacific Biosciences PACB Stock Holding History

Atom Investors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-17,161	Closed	-$22K	–	755
2025 Q3	$22K	Buy	+17,161	New	+$23.2K	﹤0.01%	582
2024 Q4	–	Sell	-17,605	Closed	-$29.9K	–	601
2024 Q3	$29.9K	Buy	+17,605	New	+$28.9K	﹤0.01%	453
2024 Q2	–	Sell	-26,751	Closed	-$100K	–	612
2024 Q1	$100K	Buy	+26,751	New	+$157K	0.01%	521

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Atom Investors's PACB Position: Q4 2025 in Review

Atom Investors sold out of Pacific Biosciences (PACB) in Q4 2025, closing a stake of 17,161 shares — an estimated $22K sold.

Atom Investors first reported a position in PACB in Q1 2024 and held it in 3 quarters. The position peaked at $100K in Q1 2024. 215 funds tracked by Wall St. Rank hold PACB as of Q4 2025.

Atom Investors reported no remaining Pacific Biosciences position as of Q4 2025 after selling out during the quarter.
Atom Investors sold 17,161 Pacific Biosciences shares in Q4 2025, an estimated $22K.
Atom Investors first reported a position in Pacific Biosciences in Q1 2024 and held it in 3 quarters.
Atom Investors's Pacific Biosciences position peaked at $100K in Q1 2024.
215 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.